Meeder Asset Management’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Meeder Asset Management’s Portfolio FPRX Stock Details FPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-355	Closed	-$2K	–	2641
2019 Q4	$2K	Buy	+355	New	+$1.41K	﹤0.01%	2086
2019 Q3	–	Sell	-1,883	Closed	-$11K	–	2326
2019 Q2	$11K	Buy	1,883 +1,449	+334%	+$13.9K	﹤0.01%	1439
2019 Q1	$6K	Buy	434 +112	+35%	+$1.28K	﹤0.01%	1377
2018 Q4	$3K	Buy	+322	New	+$3.83K	﹤0.01%	1545
2018 Q1	–	Sell	-230	Closed	-$5K	–	1814
2017 Q4	$5K	Sell	230 -7	-3%	-$225	﹤0.01%	1337
2017 Q3	$10K	Sell	237 -317	-57%	-$9.95K	﹤0.01%	1086
2017 Q2	$17K	Hold	554	–	–	﹤0.01%	867
2017 Q1	$20K	Sell	554 -275	-33%	-$12.1K	﹤0.01%	728
2016 Q4	$42K	Buy	+829	New	+$43.6K	﹤0.01%	584
2016 Q3	–	Sell	-6,480	Closed	-$268K	–	1012
2016 Q2	$268K	Buy	+6,480	New	+$282K	0.03%	530
2016 Q1	–	Sell	-462	Closed	-$19K	–	960
2015 Q4	$19K	Buy	+462	New	+$15.5K	﹤0.01%	743

Other funds holding FPRX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Meeder Asset Management's FPRX Position: Q1 2020 in Review

Meeder Asset Management sold out of Five Prime Therapeutics, Inc. (FPRX) in Q1 2020, closing a stake of 355 shares — an estimated $2K sold.

Meeder Asset Management first reported a position in FPRX in Q4 2015 and held it in 11 quarters. The position peaked at $268K in Q2 2016. 87 funds tracked by Wall St. Rank hold FPRX as of Q1 2020.

Meeder Asset Management reported no remaining Five Prime Therapeutics, Inc. position as of Q1 2020 after selling out during the quarter.
Meeder Asset Management sold 355 Five Prime Therapeutics, Inc. shares in Q1 2020, an estimated $2K.
Meeder Asset Management first reported a position in Five Prime Therapeutics, Inc. in Q4 2015 and held it in 11 quarters.
Meeder Asset Management's Five Prime Therapeutics, Inc. position peaked at $268K in Q2 2016.
87 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q1 2020.

Based on Meeder Asset Management's 13F filing for Q1 2020, filed 15 May 2020.